Vorsitzender des Aufsichtsrats – Jan H. Egberts, M.D. has over 25 years of experience in the pharmaceutical and medical devices sector. Dr Egberts gained his medical qualifications from Erasmus University Medical School in the Netherlands and obtained his MBA from Stanford. After Stanford, he joined McKinsey & Co. as a strategic consultant in New York. Dr Egberts subsequently held various business development and general management positions of increasing responsibility in the USA at Merck & Co. and Johnson & Johnson. While at Johnson & Johnson, he initiated the leveraged buy out of the BARRIER surgical business from Johnson & Johnson and the subsequent merger with Mölnlycke Health Care. After the divestiture of Molnlycke Health Care to Regent Medical he served as Senior Advisor, Healthcare Investments for 3i, the private equity firm. After his move to the Netherlands, Dr Egberts became CEO of OctoPlus, a publicly traded specialty pharmaceutical company in the Netherlands. OctoPlus was subsequently acquired by Dr Reddy Laboratories from India. After this acquisition, Dr Egberts joined Agendia, a molecular diagnostics company, initially as board member and subsequently full time as interim CEO. Currently, Dr Egberts serves as the Managing Partner of Veritas Investments, a private investment company focused on minority and controlling investments in healthcare companies. Dr Egberts also has held over 15 executive and non-executive supervisory board positions in the U.S.A. and various European countries.